Novo’s Wegovy Pill Looks A Lot Like Zepbound — In One Week – Investor’s Business Daily

Novo’s Wegovy Pill Looks A Lot Like Zepbound — In One Week  Investor’s Business Daily Novo Nordisk shares rise 8% after Wegovy obesity pill has ‘solid’ launch  CNBC Lubbock Doctor compares weight loss injections to new pills  KCBD Novo Nordisk Stock Jumps. The Wegovy Pill Is Back in Focus  Yahoo Finance Novo Nordisk sees pills capturing over third of […]

Novo’s Wegovy pill tracks 3,071 prescriptions in first days of launch – Reuters

Novo’s Wegovy pill tracks 3,071 prescriptions in first days of launch  Reuters Novo Nordisk shares rise 8% after Wegovy obesity pill has ‘solid’ launch  CNBC Lubbock Doctor compares weight loss injections to new pills  KCBD Novo Nordisk Stock Jumps. The Wegovy Pill Is Back in Focus  Yahoo Finance Novo Nordisk sees pills capturing over third of GLP-1 obesity market […]

Incretin Based Therapy in Heart Failure with Preserved Ejection Fraction

Join the American Heart Association for an insightful session with Dr. Clyde Yancy and Dr. Dhruv Kazi. Recent clinical trials demonstrate the efficacy of incretin-based therapies (including GLP1-RA) in the care of HFpEF patients and their pivotal role in improving patient quality of life. Dr. Clyde Yancy discusses the latest evidence from these landmark trials […]

Arthur Brooks: Do GLP-1s Make Us Happy?

In my column last Monday, I wrote about how to make better New Year’s resolutions—ones that are less likely to flop, but that are also challenging enough to provide satisfaction. Why? Because accomplishing something with a degree of struggle is the way to realize joy. I gave the example of using GLP-1 drugs for weight […]

‘Another self own’: Trump comment sparks internet rumors of president on Ozempic

President Donald Trump touted Friday his new health care plan, which he dubbed “The Great Health Care Plan” during a press conference from the White House, but his meandering remarks about a “friend” who took the weight-loss drug Ozempic quickly fueled online speculation about whether the president himself was using it. “A friend of mine […]

Signaling architecture of the glucagon-like peptide-1 receptor

The glucagon-like peptide-1 receptor (GLP-1R) is a class B1 G protein–coupled receptor and major therapeutic target in type 2 diabetes and obesity. Beyond its canonical role in Gαs/cAMP signaling, GLP-1R is increasingly recognized as an organizer of spatiotemporally defined signaling nanodomains, or “signalosomes.” This Review highlights our current knowledge on the mechanisms of assembly and […]

GLP-1 physiology and pharmacology along the gut-brain axis

Historically, antiobesity medications have been modestly effective at best, with side-effect profiles that limit compliance and often preclude the long-term therapy required to maintain weight loss. Recently developed therapies based on analogs of the gut hormone glucagon-like peptide-1 (GLP-1) have transformed the medical management of obesity, leading both to a degree of weight loss that […]